Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jaguar Animal Health ( (JAGX) ) has provided an update.
On September 28, 2025, Jaguar Health, Inc. entered into a securities purchase agreement with Brown Stone Capital Limited, agreeing to issue and sell shares and pre-funded warrants in a private placement. The proceeds from this transaction are intended for working capital, general corporate purposes, and repayment of existing convertible notes, potentially impacting the company’s financial stability and market operations.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its financial instability, characterized by high leverage and consistent losses. While there are positive signals from technical analysis and earnings call highlights, these are overshadowed by valuation concerns and financial performance challenges.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing gastrointestinal products for both humans and animals. The company aims to address unmet medical needs in the market.
Average Trading Volume: 135,230
Technical Sentiment Signal: Sell
Current Market Cap: $4.59M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.